All News

U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts.

This week, the nation turned its attention to the split rulings of 2 state federal court of appeals.

Active implementation of cost-saving measures successfully cut down expenditure at the Norris Comprehensive Cancer Center.

Uncompensated care was supposed to be a thing of the past, but it's persisting in many states not expanding Medicaid eligibility. As an alternative, for some high-cost uninsured patients, hospitals are turning to a new option.

When weighing the risk of heart disease, how the numbers are presented to patients can make all the difference.

Following the success of robotics in prostate surgeries, the technique was expected to provide comparable results for bladder cancer surgeries as well.

The University of Buffalo is working to limit patient readmissions to hospitals and ERs via use of dashboard technology.

Opdivo (Nivolumab) recently received regulatory approval in Japan for the treatment of patients with unresectable melanoma, the first global approval for a PD-1 inhibitor.

As healthcare reform advances, experts say, dermatologists face mounting pressure to prove their mettle to insurance exchanges and accountable care organizations (ACOs).

To better align the care of beneficiaries insured under both the Medicaid and Medicare programs, CMS invited states to participate in a 3-year demonstration project. However, it seems that many beneficiaries have opted out of these care coordination programs that are offered across the country.

A federal rule requiring health insurers to spend a minimum percentage of premium dollars on medical care led to more than $332 million in rebates last year, according to HHS.

The approval is a big gain for melanoma (Yervoy) and prostate cancer (Xtandi) patients in England and Wales.

However, a point to note is that this was a small cohort study without a comparator arm.

The drug has been approved for use in patient's with relapsed disease.

With diabetes costs taking double-digit increases--and expensive newer meds launching--insurers are tightening restrictions on drug use.

According to a recent survey, radiation oncologists are doing this for 7.9% less pay than they earned the year before.

Obamacare got taken for a roller-coaster ride on Tuesday when two different appeals courts took completely different takes on the latest challenges to the law.

A federal appeals court panel ruling in Washington, DC, if upheld, could majorly impact the Affordable Care Act.

HHS issued an interpretive rule that requires drug companies to provide discounts on orphan drugs sold through a federal program just months after a judge struck down the government's previous version of the rule.

The researchers found that the risk of developing cervical cancer within three years following a negative HPV test result was about half of the already low risk following a negative Pap test.

Information technology will be crucial to pushing disease prevention efforts in healthcare.

The Obama administration and state insurance regulators are developing stricter standards to address the concerns of consumers who say that many health plans under the Affordable Care Act have unduly limited their choices of doctors and hospitals, leaving them with unexpected medical bills.

Aduro joins the exclusive group of companies, so far only the big pharma, that have a successful trail of immunooncology candidates.

Changes to a hospice drug rule will reduce the types of medications that require prior authorization. Previous rules prohibited Medicare hospice patients from filling their Part D medications until they had confirmed that hospice providers did not cover them first.

Eighty-nine members of Congress have asked the Centers for Medicare & Medicaid Services to give pathologists a break and extend the hardship exemption they currently enjoy for all of Stage 3 of the Meaningful Use program.

While healthcare organizations and providers are addressing strategies for engaging patient populations in the pursuit of incentive or value-based reimbursements, payers are actively looking for ways to engage this same population as consumers in the name of healthcare reform.

Personalized medicine will be expensive in these early days of pioneering and planning. But individual genomic testing is not going to be exorbitant forever — and the ROI is gonna be big, both in patient outcomes and dollars saved.

When it comes to value-based decision making, several factors can influence physician behavior. Although many organizations rely on financial incentives, the Commonwealth Fund argued in a report released Tuesday that healthcare leaders should think beyond the dollars and dimes.